| ［1］ |
Ben Mordehai Y, Faibish H, Astman N, et al. Characteristics of patients with bullous pemphigoid: comparison of classic bullous pemphigoid to non⁃bullous pemphigoid［J］. J Eur Acad Dermatol Venereol, 2020,34（1）:161⁃165. doi: 10.1111/jdv.15883.
|
| ［2］ |
Briand C, Gourier G, Poizeau F, et al. Characteristics of pruritus in bullous pemphigoid and impact on quality of life: a prospective cohort study［J］. Acta Derm Venereol, 2020,100（18）:adv00320. doi: 10.2340/00015555⁃3683.
|
| ［3］ |
Hashimoto T, Kursewicz CD, Fayne RA, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid［J］. J Am Acad Dermatol, 2020,83（1）:53⁃62. doi: 10.1016/j.jaad.2019.07.060.
|
| ［4］ |
Ständer S, Hammers CM, Vorobyev A, et al. The impact of lesional inflammatory cellular infiltrate on the phenotype of bullous pemphigoid［J］. J Eur Acad Dermatol Venereol, 2021,35（8）:1702⁃1711. doi: 10.1111/jdv.17303.
|
| ［5］ |
de Graauw E, Sitaru C, Horn M, et al. Evidence for a role of eosinophils in blister formation in bullous pemphigoid［J］. Allergy, 2017,72（7）:1105⁃1113. doi: 10.1111/all.13131.
|
| ［6］ |
Simon D, Yousefi S, Cazzaniga S, et al. Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo⁃controlled, double⁃blind phase 2 pilot study［J］. Allergy, 2020,75（3）:669⁃672. doi: 10.1111/all.13950.
|
| ［7］ |
Astra Zeneca. A study to investigate the use of benralizumab in patients with bullous pemphigoid［EB/OL］.［2021⁃06⁃11］. https://clinicaltrials.gov/ct2/show/NCT04612790.
|
| ［8］ |
Barrios DM, Phillips GS, Geisler AN, et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti⁃HER2 therapies［J］. Ann Oncol, 2021,32（6）:736⁃745. doi: 10.1016/j.annonc.2021.02.016.
|
| ［9］ |
Seyed Jafari SM, Gadaldi K, Feldmeyer L, et al. Effects of omalizumab on FcεRI and IgE expression in lesional skin of bullous pemphigoid［J］. Front Immunol, 2019,10:1919. doi: 10.3389/fimmu.2019.01919.
|
| ［10］ |
Seyed Jafari SM, Feldmeyer L, Bossart S, et al. Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid［J］. Front Immunol, 2020,11:611549. doi: 10.3389/fimmu.2020.611549.
|
| ［11］ |
Wang F, Trier AM, Li F, et al. A basophil⁃neuronal axis promotes itch［J］. Cell, 2021,184（2）:422⁃440.e17. doi: 10.1016/j.cell.2020.12.033.
|
| ［12］ |
Rüdrich U, Gehring M, Papakonstantinou E, et al. Eosinophils are a major source of interleukin⁃31 in bullous pemphigoid［J］. Acta Derm Venereol, 2018,98（8）:766⁃771. doi: 10.2340/00015 555⁃2951.
|
| ［13］ |
Raap U, Gehring M, Kleiner S, et al. Human basophils are a source of ⁃ and are differentially activated by ⁃ IL⁃31［J］. Clin Exp Allergy, 2017,47（4）:499⁃508. doi: 10.1111/cea.12875.
|
| ［14］ |
Maglie R, Ugolini F, De Logu F, et al. Overexpression of helper T cell type 2⁃related molecules in the skin of patients with eosinophilic dermatosis of hematologic malignancy［J］. J Am Acad Dermatol, 2021,doi: 10.1016/j.jaad.2021.07.007.
|
| ［15］ |
Egeberg A, Thyssen JP, Wu JJ. Anti⁃interleukin⁃31 receptor a antibody for atopic dermatitis［J］. N Engl J Med, 2017,376（21）:2092⁃2093. doi: 10.1056/NEJMc1704013.
|
| ［16］ |
Kabashima K, Matsumura T, Komazaki H, et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus［J］. N Engl J Med, 2020,383（2）:141⁃150. doi: 10.1056/NEJMoa1917006.
|
| ［17］ |
Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate⁃to⁃severe prurigo nodularis［J］. N Engl J Med, 2020,382（8）:706⁃716. doi: 10.1056/NEJMoa1908316.
|
| ［18］ |
Campion M, Smith L, Gatault S, et al. Interleukin⁃4 and interleukin⁃13 evoke scratching behaviour in mice［J］. Exp Dermatol, 2019,28（12）:1501⁃1504. doi: 10.1111/exd.14034.
|
| ［19］ |
Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series［J］. J Am Acad Dermatol, 2020,83（1）:46⁃52. doi: 10.1016/j.jaad. 2020.01.089.
|
| ［20］ |
杨璐, 曾跃平, 晋红中. 度普利尤单抗联合糖皮质激素治疗大疱性类天疱疮:国内首报并文献复习［J］. 中华临床免疫和变态反应杂志, 2021,15（1）:47⁃52. doi: 10.3969/j.issn.1673⁃8705. 2021.01.009.
|
| ［21］ |
Kaye A, Gordon SC, Deverapalli SC, et al. Dupilumab for the treatment of recalcitrant bullous pemphigoid［J］. JAMA Dermatol, 2018,154（10）:1225⁃1226. doi: 10.1001/jamadermatol.2018.2526.
|
| ［22］ |
Regeneron Pharmaceuticals. A study to evaluate the efficacy and safety of dupilumab in adult patients with bullous pemphigoid （LIBERTY⁃BP） ［EB/OL］.［2021⁃06⁃11］. https://www.ncbi.nlm.nih.gov/search/all/?term=NCT04206553.
|
| ［23］ |
Li SZ, Jin XX, Ge XL, et al. Thymic stromal lymphopoietin is implicated in the pathogenesis of bullous pemphigoid by dendritic cells［J］. J Immunol Res, 2020,2020:4594630. doi: 10.1155/2020/4594630.
|
| ［24］ |
Mishra SK, Wheeler JJ, Pitake S, et al. Periostin activation of integrin receptors on sensory neurons induces allergic itch［J］. Cell Rep, 2020,31（1）:107472. doi: 10.1016/j.celrep.2020.03.036.
|
| ［25］ |
Mitamura Y, Nunomura S, Nanri Y, et al. The IL⁃13/periostin/IL⁃24 pathway causes epidermal barrier dysfunction in allergic skin inflammation［J］. Allergy, 2018,73（9）:1881⁃1891. doi: 10.1111/all.13437.
|
| ［26］ |
Yosipovitch G, Ständer S, Kerby MB, et al. Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo⁃controlled phase 2 clinical trial［J］. J Am Acad Dermatol, 2018,78（5）:882⁃891.e10. doi: 10.1016/j.jaad. 2018.02.030.
|
| ［27］ |
Ständer S, Kwon P, Hirman J, et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2019,80（5）:1395⁃1402. doi: 10.1016/j.jaad.2019.01.052.
|
| ［28］ |
Pariser DM, Bagel J, Lebwohl M, et al. Serlopitant for psoriatic pruritus: a phase 2 randomized, double⁃blind, placebo⁃controlled clinical trial［J］. J Am Acad Dermatol, 2020,82（6）:1314⁃1320. doi: 10.1016/j.jaad.2020.01.056.
|
